Keywords: seragen, ph, iii, il-2, fusion, toxin, trials

Seragen's Ph III IL-2 Fusion Toxin Trials

Article | 02 January 1995

Print This

Seragen has started the Phase III clinical trials program for its interleukin-2 fusion toxin product for the treatment of cutaneous ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in